Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller
Key takeaways
- Jim Cramer Says “Let Immunity Bio Be Your Speculation” to a Caller Syeda Seirut Javed Fri, June 19, 2026 at 8:35 PM GMT+7 2 min read IBRX SPCX Immunity Bio, Inc.
- Remember, in How to Make Money in Any Market, I encourage speculation as long as it’s only one position.
- (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers.
Jim Cramer Says “Let Immunity Bio Be Your Speculation” to a Caller Syeda Seirut Javed Fri, June 19, 2026 at 8:35 PM GMT+7 2 min read IBRX SPCX Immunity Bio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that Space X investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked:
I think that’s a good way to look at it. But I will tell you that’s going to be your spec. Remember, in How to Make Money in Any Market, I encourage speculation as long as it’s only one position. If you own two positions, then I don’t encourage it. Let ImmunityBio be your speculation.
ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller inquired about the stock during the April 17 episode, and Cramer commented: